EQS-News: Eckert & Ziegler Achieves Further Earnings Growth and Double-Digit Sales Growth in the Medical Segment

Eckert & Ziegler SE · ISIN: DE0005659700 · EQS - Company News

Country: Germany · Primary market: Germany · EQS NID: 2228556

EQS-News: Eckert & Ziegler SE / Key word(s): 9 Month figures/Quarter Results
Eckert & Ziegler Achieves Further Earnings Growth and Double-Digit Sales Growth in the Medical Segment

13.11.2025 / 07:45 CET/CEST
The issuer is solely responsible for the content of this announcement.

3^rd quarter of 2025:

Sales of €75.3 million (previous year: €70.1 million)
EBIT before special items of €15.4 million (previous year: €14.2 million)
Net income of €8.5 million (previous year: €5.3 million)

First 9 months of 2025:

Sales of €224.1 million (previous year: €215.5 million)
EBIT before special items of €50.8 million (previous year: €46.7 million)
Net income of €29.9 million (previous year: €23.4 million)

Forecast for 2025:

Sales of approx. €320 million (confirmed)
EBIT before special items of approx. €78 million (confirmed)

Berlin, 13 November 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) increased sales in the first nine months of 2025 by 4% to €224.1 million compared to the same period last year. EBIT before special items from continuing operations (adjusted EBIT) rose by 9% to €50.8 million. Net profit (from continuing and discontinued operations) grew by 28% to €29.9 million, or €0.48 per share.

In the Medical segment, sales in the first nine months of the year amounted to €119.7 million, up around €15.2 million or 15% on the previous year's level. The business with pharmaceutical radioisotopes remains the most important source of revenue. Particularly noteworthy here are the developments in sales of generators, licensing, and contract manufacturing & development (CDMO).

The Isotope Products segment generated external sales of €104.4 million, down €6.6 million or approximately 6% compared to the first nine months of the previous year. Shifts between product groups toward lower-margin products have become apparent in comparison to the same period last year.

For the current fiscal year 2025, the Executive Board confirms its profit forecast published on March 27, 2025, with sales of approx. €320 million and an adjusted EBIT of approx. €78 million.

The complete quarterly report can be viewed here: https://www.ezag.com/Q32025en

About Eckert & Ziegler.
Eckert & Ziegler SE, with more than 1.000 employees, is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Your contact:
Eckert & Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com

13.11.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News

Language:	English
Company:	Eckert & Ziegler SE
	Robert-Rössle-Str.10
	13125 Berlin
	Germany
Phone:	+49 30 941084-138
Fax:	+49 30 941084-0
Internet:	www.ezag.de
ISIN:	DE0005659700
WKN:	565970
Indices:	SDAX, TecDax,
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID:	2228556


End of News	EQS News Service

2228556 13.11.2025 CET/CEST

More Research

Company related KPIs

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
	2019	2020	2021	2022	2023	2024	2025e
Sales¹	178,49	176,14	180,44	222,26	246,09	295,85	320,00
EBITDA^1,2	43,13	44,64	57,04	55,52	58,83	78,80	90,00
EBITDA-Margin³	24,16	25,34	31,61	24,98	23,91	26,64	28,13
EBIT^1,4	32,06	33,69	47,45	44,54	45,45	59,95	77,00
EBIT-Margin⁵	17,96	19,13	26,30	20,04	18,47	20,26	24,06
Net Profit (Loss)¹	22,48	23,11	34,66	29,75	26,77	34,11	50,00
Net-Margin⁶	12,60	13,12	19,21	13,39	10,88	11,53	15,63
Cashflow^1,7	40,43	36,79	33,86	34,30	47,40	66,57	72,00
Earnings per share⁸	0,36	0,37	0,55	0,47	0,42	0,53	0,78
Dividend per share⁸	0,14	0,15	0,17	0,17	0,02	0,17	0,18

Quelle: boersengefluester.de and Company information

Explanation

¹ in Mio. Euro; ² EBITDA = Earnings before interest, taxes, depreciation and amortisation; ³ EBITDA in relation to sales; ⁴ EBIT = Earnings before interest and taxes; ⁵ EBIT in relation to sales; ⁶ Net profit (-loss) in relation to sales; ⁷ Cashflow from operations; ⁸ in Euro; Source: boersengefluester.de

Auditor: Forvis Mazars

Company Snapshot

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Eckert & Ziegler
WKN	ISIN	Legal Type	Marketcap	IPO	Recommendation	Plus Code
565970	DE0005659700	SE	982,59 Mio €	25.05.1999	Kaufen	9F4MJGG3+WR

* * *

PE 2026e	PE 10Y-Ø	BGFL-Ratio	Shiller-PE	PB	PCF	KUV
18,42	27,31	0,67	12,50	4,61	14,76	3,32

Dividends

Dividend '2023 in €	Dividend '2024 in €	Dividend '2025e in €	Div.-Yield '2025e in %
0,02	0,17	0,18	1,16%

Financial calendar

Annual General Meeting	Q1-figures	Q2-figures	Q3-figures	Annual press conference
24.06.2026	12.05.2026	13.08.2026	13.11.2025	26.03.2026

Performance

Distance 60-days-line	Distance 200-days-line	Performance YtD	Performance 52 weeks	IPO	Last Price (EoD) +0,32% 15,47 € ATH 47,13 €
-8,18%	-18,16%	+4,29%	-2,13%	+706,99%	Last Price (EoD) +0,32% 15,47 € ATH 47,13 €

LEI: 391200EUDABLUKXCKG48

Social media-channel

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.

EQS-News: Eckert & Ziegler Achieves Further Earnings Growth and Double-Digit Sales Growth in the Medical Segment

Quick Links

Network

Partner

Contact

EQS-News: Eckert & Ziegler Achieves Further Earnings Growth and Double-Digit Sales Growth in the Medical Segment

Would you like to see fewer adverts? Simply register for a user account. Registration is free and significantly reduces the number of adverts.

Quick Links

Network

Partner

Contact